Mark Siedner News Today

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

New data could also give insight on how to manage it

Over 20% of patients taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, suffer from the rebound, compared to less than the 2% chance seen in other treatment groups, a Harvard Medical

Pfizer Inc.s Paxlovid was linked to a high rate of Covid rebound in a small study that suggests people taking the pill, along with their families and close contacts, should

<p>A new study by investigators from <a href="https://www.massgeneralbrigham.org/">Mass General Brigham</a> found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test—a phenomenon known as virologic rebound. By contrast, people not taking Paxlo...

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test-;a phenomenon known as virologic rebound.

People not taking Paxlovid experienced the viral rebound phenomenon only about two per cent of the time, the researchers at the Mass General Brigham hospital, Boston, US, found. Paxlovid, which is a Nirmatrelvir-ritonavir therapy taken orally, has been previously studied to be effective in reducing hospitalisation and death in severe COVID-19 infections.

One in five people who take nirmatrelvir/ritonavir (Paxlovid) get COVID-19 again after the drug clears them of it, according to a new study.

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test—a phenomenon known as virologic rebound.

A study by researchers at Mass General Brigham hospital in Boston found that one in five COVID-infected individuals treated with antiviral medication Paxlovid experienced viral rebound, shedding live and potentially contagious virus after an initial negative test. The rebound phenomenon was more common than expected, occurring over 20% of the time with Paxlovid. The study highlights the need for patient counseling and re-testing during Paxlovid treatment, despite its effectiveness in reducing ho...